profit from every $100 of sales.
$0$100
Keros Therapeutics
$10.30+2.18% today
-40.5% in 1 year
1-year low $9.171-year high $21.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $2.32 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Keros Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $244 million in 2025, with $87.0 million of profit last year.
SalesProfit
Keros Therapeutics handed back more cash to shareholders than it generated last year.
Buybacks $375M
Free cash flow 2025$106M
Bought back its own shares$375M
Paid as dividends–
Cash vs. debt$287M vs. $17M
Keros Therapeutics vs. similar companies
Keros Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Keros Therapeutics | 2.3× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Keros Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 4 | 244 | |
| – | – | – | – | |
| -108 | -168 | -210 | 68 | |
| -104 | -152 | -208 | 69 | |
| -105 | -153 | -187 | 87 | |
| -4.15 | -5.20 | -5.00 | 2.30 | |
| – | – | – | – | |
| – | -110,954.3% | -5,904.1% | 27.7% | |
| – | -101,319.2% | -5,277.5% | 35.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 307 | 370 | 616 | 338 |
| Cash | 279 | 331 | 560 | 287 |
| Total debt | 13 | 14 | 19 | 17 |
| Total liabilities | 29 | 38 | 44 | 35 |
| 277 | 332 | 572 | 303 | |
| 23 | 29 | 37 | 38 | |
| -28.4% | -34.9% | -28.0% | 16.7% | |
| -37.7% | -46.1% | -32.8% | 28.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -70 | -125 | -161 | 108 | |
| 1 | 2 | 2 | 2 | |
| -71 | -127 | -163 | 106 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 375 | |
| 19 | 29 | 35 | 29 |
Valuation
- 2.3×
- –
- –
- 1.3×
- 0.8×
- 1.9×
- –
- 52.4%
- 43.0%
- 0.0%
Profitability
- 96.5%
- 27.7%
- 35.7%
- -286.9%
- -34.5%
- -21.7%
- -17.0%
- -27.3%
- -36.9%
- 292.4%
Growth
- +3,920.3%
- –
- +165.1%
- –
- +12.4%
Financial health
- 2.8×
- 0.06
- 5.2%
- –
- 22.62
- 22.62
- 0.11
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Top 11%of 884
Top 1%of 601
Top 1%of 987
What analysts expect
- Average price target
- $102.60
- Range
- $96.00 – $107.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.21 | -1.02 | −18.3% |
| Mar 4, 2026 | -0.86 | -0.49 | −75.5% |
| Nov 5, 2025 | -0.18 | -1.11 | +83.8% |
| Aug 6, 2025 | -0.76 | -1.14 | +33.3% |
| May 6, 2025 | 3.62 | -0.01 | +36,300.0% |
| Feb 26, 2025 | -1.14 | -1.36 | +16.2% |
| Nov 6, 2024 | -1.41 | -1.26 | −11.9% |
| Aug 7, 2024 | -1.25 | -1.23 | −1.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
83Pass
Philip Fisher
70Pass
Peter Lynch
100Pass
Joel Greenblatt
39No pass
Charlie Munger
58No pass
Terry Smith
57No pass
Questions about Keros Therapeutics
Is Keros Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Keros Therapeutics AI analysis
What does Keros Therapeutics do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. It is in Biotechnology.
Does Keros Therapeutics pay a dividend?
No. Keros Therapeutics does not pay a dividend at the moment; in 2025 it returned $375 million to shareholders by buying back its own shares.
Is Keros Therapeutics stock halal?
No. Keros Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 142% of its market value, at or above the 33% limit. How we check
How has Keros Therapeutics stock done over the past year?
Down 40.5% over the past twelve months, to $10.30. It traded between $9.17 and $21.84 and is 52.8% below its high.
Who are Keros Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Keros Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.